HRP20110622T1 - Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede - Google Patents
Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede Download PDFInfo
- Publication number
- HRP20110622T1 HRP20110622T1 HR20110622T HRP20110622T HRP20110622T1 HR P20110622 T1 HRP20110622 T1 HR P20110622T1 HR 20110622 T HR20110622 T HR 20110622T HR P20110622 T HRP20110622 T HR P20110622T HR P20110622 T1 HRP20110622 T1 HR P20110622T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- inhibitor
- ischemia
- reperfusion injury
- intended
- Prior art date
Links
- 206010063837 Reperfusion injury Diseases 0.000 title claims abstract 7
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 208000012947 ischemia reperfusion injury Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 208000028867 ischemia Diseases 0.000 claims abstract 8
- 230000010410 reperfusion Effects 0.000 claims abstract 4
- 102000055157 Complement C1 Inhibitor Human genes 0.000 claims 6
- 108700040183 Complement C1 Inhibitor Proteins 0.000 claims 6
- 241001465754 Metazoa Species 0.000 claims 5
- 230000009261 transgenic effect Effects 0.000 claims 4
- WPAHVUADNLXSOM-SNVBAGLBSA-N 3-[5-chloro-6-[(1R)-1-pyridin-2-ylethoxy]-1,2-benzoxazol-3-yl]propanoic acid Chemical compound ClC=1C(=CC2=C(C(=NO2)CCC(=O)O)C=1)O[C@H](C)C1=NC=CC=C1 WPAHVUADNLXSOM-SNVBAGLBSA-N 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003527 fibrinolytic agent Substances 0.000 claims 2
- 125000005629 sialic acid group Chemical group 0.000 claims 2
- 229960000103 thrombolytic agent Drugs 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 1
- 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 claims 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 1
- 241000283953 Lagomorpha Species 0.000 claims 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 102000044507 human SERPING1 Human genes 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000009984 peri-natal effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 abstract 2
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
Upotreba inhibitora C1 koji smanjuje razinu terminalnih ostataka sijalinske kiseline u usporedbi s ljudskim inhibitorom C1 iz plazme, gdje smanjena razina terminalnih ostataka sijalinske kiseline rezultira poluvijekom u plazmi kraćim od 6 sata, naznačena time što je inhibitor C1 namijenjen pripravi farmaceutskog pripravka namijenjenog sprječavanju, smanjivanju ili liječenju najmanje jednog od ishemije i reperfuzijske ozljede, gdje se inhibitor C1 primijenjuje najmanje 10 minuta nakon trajanja ishemije i/ili početka reperfuzije. Patent sadrži još 14 patentnih zahtjeva.
Claims (15)
1. Upotreba inhibitora C1 koji smanjuje razinu terminalnih ostataka sijalinske kiseline u usporedbi s ljudskim inhibitorom C1 iz plazme, gdje smanjena razina terminalnih ostataka sijalinske kiseline rezultira poluvijekom u plazmi kraćim od 6 sata, naznačena time što je inhibitor C1 namijenjen pripravi farmaceutskog pripravka namijenjenog sprječavanju, smanjivanju ili liječenju najmanje jednog od ishemije i reperfuzijske ozljede, gdje se inhibitor C1 primijenjuje najmanje 10 minuta nakon trajanja ishemije i/ili početka reperfuzije.
2. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što inhibitor C1 se primijenjuje između najmanje 10 minuta i 24 sata nakon trajanja ishemije i/ili početka reperfuzije.
3. Upotreba u skladu s patentnim zahtjevom 1 ili 2, naznačena time što inhibitor C1 sadrži glikan, koji je terminalni ostatak kojeg se bira između galaktoze, N-acetilgalaktozamina, N-acetilglukozamina, manoze i fukoze.
4. Upotreba u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačena time što inhibitor C1 ima aminokiselinski slijed koji je najmanje 65% identičan aminokiselinskom slijedu iz SEQ ID NO:1.
5. Upotreba u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačena time što inhibitor C1 se dobiva iz genetski modificirane stanice ili organizma.
6. Upotreba u skladu s patentnim zahtjevom 5, naznačena time što navedeni organizam je transgena životinja koja nije čovjek.
7. Upotreba u skladu s patentnim zahtjevom 6, naznačena time što inhibitor C1 se dobiva iz mlijeka navedene transgene životinje koja nije čovjek.
8. Upotreba u skladu s patentnim zahtjevom 6 ili 7, naznačena time što transgena životinja koja nije čovjek je govedo ili životinja iz reda Lagomorpha.
9. Upotreba u skladu s patentnim zahtjevom 8, naznačena time što transgena životinja koja nije čovjek je kunić.
10. Upotreba u skladu s bilo kojim od patentnih zahtjeva 1-9, naznačena time što inhibitor C1 se upotrebljava u rasponu količina od 50-2000 jedinica po kg tjelesne težine.
11. Upotreba u skladu s bilo kojim od patentnih zahtjeva 1-10, naznačena time što farmaceutski pripravak također sadrži trombolitičko sredstvo, ili je namijenjen upotrebi u kombinaciji s trombolitičkim sredstvom, ili je namijenjen upotrebi nakon liječenja s takvim sredstvom.
12. Upotreba u skladu s bilo kojim od patentnih zahtjeva 1-11, naznačena time što farmaceutski pripravak je namijenjen sprječavanju, smanjivanju ili liječenju neočekivane iznenadne ili akutne pojave ishemije i reperfuzijske ozljede.
13. Upotreba u skladu s patentnim zahtjevom 12, naznačena time što do neočekivane iznenadne ili akutne pojava ishemije i reperfuzijske ozljede dolazi nakon inzulta ili perinatalnog inzulta.
14. Upotreba u skladu s bilo kojim od patentnih zahtjeva 1-11, naznačena time što farmaceutski pripravak je namijenjen sprječavanju, smanjivanju ili liječenju očekivane pojave ishemije i reperfuzijske ozljede.
15. Upotreba u skladu s patentnim zahtjevom 14, naznačena time što do očekivane pojave ishemije i reperfuzijske ozljede dolazi nakon presađivanja organa.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05112630 | 2005-12-21 | ||
US76094406P | 2006-01-23 | 2006-01-23 | |
PCT/NL2006/050321 WO2007073186A2 (en) | 2005-12-21 | 2006-12-19 | Use of c1 inhibitor for the prevention of ischemia-reperfusion injury |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20110622T1 true HRP20110622T1 (hr) | 2011-09-30 |
Family
ID=38016640
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110622T HRP20110622T1 (hr) | 2005-12-21 | 2011-08-25 | Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede |
HRP20171738TT HRP20171738T1 (hr) | 2005-12-21 | 2017-11-13 | Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171738TT HRP20171738T1 (hr) | 2005-12-21 | 2017-11-13 | Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede |
Country Status (15)
Country | Link |
---|---|
US (3) | US8071532B2 (hr) |
EP (2) | EP2380587B1 (hr) |
JP (2) | JP5394748B2 (hr) |
KR (1) | KR101508668B1 (hr) |
AT (1) | ATE516043T1 (hr) |
AU (1) | AU2006327989B2 (hr) |
CA (1) | CA2632400C (hr) |
CY (2) | CY1112452T1 (hr) |
DK (1) | DK2380587T3 (hr) |
HR (2) | HRP20110622T1 (hr) |
IL (2) | IL192180A (hr) |
NZ (1) | NZ568749A (hr) |
PL (2) | PL1965831T3 (hr) |
SI (1) | SI2380587T1 (hr) |
WO (1) | WO2007073186A2 (hr) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2502539A1 (en) * | 2002-10-17 | 2004-04-29 | Pharming Intellectual Property B.V. | Protein modification |
PL1965831T3 (pl) | 2005-12-21 | 2011-12-30 | Pharming Intellectual Property B V | Zastosowanie inhibitora C1 do profilaktyki uszkodzenia niedokrwienno-reperfuzyjnego |
EP3028716B1 (en) * | 2006-10-10 | 2020-09-16 | Regenesance B.V. | Complement inhibition for improved nerve regeneration |
JP5423266B2 (ja) * | 2009-09-14 | 2014-02-19 | 富士電機株式会社 | デジタル制御スイッチング電源装置 |
EP2497489A1 (en) * | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
CA2829037C (en) * | 2011-03-09 | 2022-05-17 | Csl Behring Gmbh | Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
ES2714999T3 (es) | 2011-09-24 | 2019-05-31 | Csl Behring Gmbh | Terapia de combinación que usa inmunoglobulina e inhibidor de C1 |
WO2013082458A1 (en) | 2011-12-02 | 2013-06-06 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
JP6127063B2 (ja) * | 2011-12-22 | 2017-05-10 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 中枢神経系の続発性浮腫の治療のためのc1インヒビターの使用 |
WO2014008242A1 (en) * | 2012-07-03 | 2014-01-09 | The Trustees Of Columbia University In The City Of New York | The use of interleukin-11 to protect against ischemia and reperfusion injury |
WO2014066744A2 (en) | 2012-10-25 | 2014-05-01 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
GB2509260B (en) | 2012-11-02 | 2016-05-04 | True North Therapeutics Inc | Anti-complement C1s antibodies and uses thereof |
ES2609070T3 (es) * | 2013-02-28 | 2017-04-18 | Csl Behring Gmbh | Agente terapéutico para el embolismo de líquido amniótico |
EP2964255B1 (en) * | 2013-03-08 | 2020-11-04 | CSL Behring GmbH | Treatment and prevention of remote ischemia-reperfusion injury |
EP2968434B1 (en) | 2013-03-15 | 2017-06-28 | Shire Viropharma Incorporated | C1-inh compositions for use in the prevention and treatment of hereditary angioedema (hae). |
EP3013366B1 (en) * | 2013-06-28 | 2021-08-25 | CSL Behring GmbH | Combination therapy using a factor xii inhibitor and a c1-inhibitor |
ES2788697T3 (es) * | 2014-11-03 | 2020-10-22 | Thrombolytic Science Llc | Métodos y composiciones para trombólisis segura y eficaz |
US10729767B2 (en) | 2015-04-06 | 2020-08-04 | Bioverativ Usa Inc. | Humanized anti-C1s antibodies and methods of inhibiting C1s cleavage |
WO2016196070A1 (en) | 2015-06-03 | 2016-12-08 | Children's Hospital Medical Center | Compositions and methods for treating neonatal biliary atresia |
JP7189767B2 (ja) * | 2015-11-19 | 2022-12-14 | 武田薬品工業株式会社 | 組換えヒトc1エステラーゼインヒビター及びその使用 |
CN109562149A (zh) | 2016-08-05 | 2019-04-02 | 德国杰特贝林生物制品有限公司 | C1酯酶抑制剂的药物制剂 |
AU2017316513A1 (en) | 2016-08-23 | 2019-03-28 | Csl Behring Gmbh | Method of preventing acute attacks of hereditary angioedema associated with C1 esterase inhibitor deficiency |
US11154596B2 (en) | 2017-06-16 | 2021-10-26 | Thrombolytic Science, Llc | Methods for thrombolysis |
CA3075686A1 (en) | 2017-09-15 | 2019-03-21 | Cedars-Sinai Medical Center | Methods for improving organ function in organ transplant patients |
WO2019166572A1 (en) | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor |
EP3758739B1 (en) | 2018-02-28 | 2024-05-15 | Pharming Intellectual Property B.V. | Treatment and prevention of pre-eclampsia |
JP2022505307A (ja) | 2018-10-17 | 2022-01-14 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | C1-inhを精製する方法 |
US20220363715A1 (en) | 2019-07-04 | 2022-11-17 | Csl Behring Gmbh | Process for Purifying C1-INH |
KR102191500B1 (ko) | 2020-03-30 | 2020-12-15 | 국립낙동강생물자원관 | 초석잠 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물 |
EP3895726A1 (en) | 2020-04-17 | 2021-10-20 | Pharming Intellectual Property BV | Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress |
KR102217607B1 (ko) | 2020-06-01 | 2021-02-18 | 국립낙동강생물자원관 | 석창포 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물 |
KR102191452B1 (ko) | 2020-06-30 | 2020-12-15 | 주식회사 에이치비헬스케어 | 곶감 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물 |
CA3198740A1 (en) | 2020-11-20 | 2022-05-27 | John Roberts | Method for treating antibody-mediated rejection |
EP4366761A1 (en) | 2021-07-09 | 2024-05-15 | Pharming Intellectual Property B.V. | Using c1 esterase inhibitor to treat viral infection-related symptoms |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1402897E (pt) | 1999-05-14 | 2007-01-31 | Jens Christian Jensenius | Novas indicações de lectina de ligação a manana (mbl) no tratamento de indivíduos imunocomprometidos |
US7067713B2 (en) * | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
JP2003521914A (ja) * | 2000-01-31 | 2003-07-22 | ファーミング インテレクチュアル プロパティー ベー.フェー. | トランスジェニック哺乳動物の乳汁に産生されるc1インヒビター |
JP2004100982A (ja) * | 2002-09-05 | 2004-04-02 | Denso Corp | 熱交換器 |
CA2502539A1 (en) * | 2002-10-17 | 2004-04-29 | Pharming Intellectual Property B.V. | Protein modification |
PL1626736T3 (pl) * | 2003-05-16 | 2021-05-04 | Pharming Intellectual Property B.V. | Inhibitor c1 o krótkim okresie półtrwania do leczenia przejściowego |
PL1965831T3 (pl) | 2005-12-21 | 2011-12-30 | Pharming Intellectual Property B V | Zastosowanie inhibitora C1 do profilaktyki uszkodzenia niedokrwienno-reperfuzyjnego |
-
2006
- 2006-12-19 PL PL06824316T patent/PL1965831T3/pl unknown
- 2006-12-19 AT AT06824316T patent/ATE516043T1/de active
- 2006-12-19 US US12/158,987 patent/US8071532B2/en active Active
- 2006-12-19 EP EP11172880.4A patent/EP2380587B1/en active Active
- 2006-12-19 SI SI200632219T patent/SI2380587T1/en unknown
- 2006-12-19 JP JP2008547134A patent/JP5394748B2/ja active Active
- 2006-12-19 NZ NZ568749A patent/NZ568749A/en unknown
- 2006-12-19 AU AU2006327989A patent/AU2006327989B2/en active Active
- 2006-12-19 PL PL11172880T patent/PL2380587T3/pl unknown
- 2006-12-19 KR KR1020087017880A patent/KR101508668B1/ko active IP Right Grant
- 2006-12-19 CA CA2632400A patent/CA2632400C/en active Active
- 2006-12-19 EP EP06824316A patent/EP1965831B1/en active Active
- 2006-12-19 DK DK11172880.4T patent/DK2380587T3/en active
- 2006-12-19 WO PCT/NL2006/050321 patent/WO2007073186A2/en active Application Filing
-
2008
- 2008-06-15 IL IL192180A patent/IL192180A/en active IP Right Grant
-
2011
- 2011-08-25 HR HR20110622T patent/HRP20110622T1/hr unknown
- 2011-10-05 CY CY20111100950T patent/CY1112452T1/el unknown
- 2011-10-11 US US13/271,107 patent/US8415288B2/en active Active
-
2013
- 2013-02-04 JP JP2013019186A patent/JP2013126992A/ja active Pending
- 2013-02-25 US US13/776,529 patent/US9211318B2/en active Active
- 2013-10-17 IL IL228954A patent/IL228954A/en active IP Right Grant
-
2017
- 2017-11-13 HR HRP20171738TT patent/HRP20171738T1/hr unknown
-
2018
- 2018-01-10 CY CY20181100029T patent/CY1119818T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20110622T1 (hr) | Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede | |
US9730984B2 (en) | Composition for preventing or treating rheumatoid arthritis | |
JOP20210262A1 (ar) | تركيبة صيدلانية، تشمل متغير ودواء هيالورونيداز ph20 البشرى، للحقن تحت الجلد | |
HK1115154A1 (en) | Glycosylated il-7, preparation and uses | |
RU2014117291A (ru) | Рекомбинантный человеческий белок naglu и его применение | |
PL402948A1 (pl) | Kwasy tluszczowe o sredniej dlugosci lancucha, glicerydy i analogi jako czynniki zwiekszajace przezycie i aktywacje neutrofili | |
DE60335101D1 (de) | Antimikrobielles polypeptid und nutzung davon | |
WO2000049040A3 (en) | Antimicrobial/endotoxin neutralizing polypeptide | |
NZ596043A (en) | Allergy inhibitor compositions and kits and methods of using the same | |
AU2014318247B2 (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
WO2005053610A3 (en) | Diamine and iminodiacetic acid hydroxamic acid derivatives | |
NZ614557A (en) | Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use | |
CA2748392C (en) | Use of interleukin-22 for the prevention and/or treatment of multiple organ dysfunction syndrome (mods) | |
MX2007002491A (es) | Uso farmaceutico de graptopetalo y plantas relacionadas. | |
CA3059094A1 (en) | C4bp-based compounds for treating immunological diseases | |
BRPI0411865A (pt) | redução da descoloração em espumas brancas de poliuretano | |
IL162714A0 (en) | Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis | |
CA2339870A1 (en) | Antithrombin nucleotides and proteins from horn fly | |
Kaplan et al. | Genetic Modification of Response to Spleen Shielding in Irradiated Mice. | |
WO2008149428A1 (ja) | 自己免疫疾患、炎症及び神経疾患の治療剤及び予防剤 | |
MX2023001565A (es) | Vectores aav que codifican parkin y usos de los mismos. | |
Becerıklısoy et al. | Effectiveness of Thuja occidentalis and Urtica urens in pseudopregnant bitches. | |
CZ285155B6 (cs) | Peptidy s organoprotektivním účinkem, způsob jejich výroby a farmaceutické prostředky s jejich obsahem | |
AR127311A1 (es) | VACUNAS DE ÁCIDOS NUCLEICOS PARA EL CORONAVIRUS BASADAS EN SECUENCIAS DERIVADAS DE LA CEPA DELTA DEL SARS-CoV-2 | |
AR127675A1 (es) | Terapia génica para el tratamiento de la ht1 |